Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.54 USD | +1.04% | +5.78% | +44.35% |
Apr. 24 | Alvotech’s Simponi Biosimilar Candidate Shows Efficacy in Confirmatory Study | MT |
Apr. 19 | Sector Update: Health Care Stocks Advance Late Afternoon | MT |
Financials (USD)
Sales 2024 * | 321M | Sales 2025 * | 606M | Capitalization | 3.79B |
---|---|---|---|---|---|
Net income 2024 * | -149M | Net income 2025 * | 30M | EV / Sales 2024 * | 16.3 x |
Net Debt 2024 * | 1.46B | Net Debt 2025 * | 1.28B | EV / Sales 2025 * | 8.35 x |
P/E ratio 2024 * |
-22.7
x | P/E ratio 2025 * |
131
x | Employees | 999 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 27.24% |
Latest transcript on Alvotech
1 day | +1.04% | ||
Current month | +44.35% | ||
Current year | +44.35% |
Managers | Title | Age | Since |
---|---|---|---|
Vilhelm Wessman
CEO | Chief Executive Officer | 54 | 18-11-01 |
Joel Morales
DFI | Director of Finance/CFO | 46 | 20-01-31 |
Giedrius Zunda
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Linda McGoldrick
BRD | Director/Board Member | 68 | 22-06-15 |
Helga Zharov
LAW | General Counsel | 57 | 20-04-30 |
Vilhelm Wessman
CEO | Chief Executive Officer | 54 | 18-11-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 13.54 | +1.04% | 191,089 |
24-04-23 | 13.4 | +0.53% | 195,834 |
24-04-22 | 13.33 | +0.83% | 184,812 |
24-04-19 | 13.22 | +2.56% | 1,686,575 |
24-04-18 | 12.89 | +0.70% | 90,150 |
Delayed Quote Nyse, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.09% | 43.84B | |
+47.81% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- ALVO Stock
- ALVO Stock